Chordoma clinical trials at UCSF
2 in progress, 1 open to eligible people
Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
open to eligible people ages 6 months to 40 years
This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.
San Francisco, California and other locations
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
Sorry, currently not accepting new patients, but might later
This phase I/II trial studies how well tiragolumab and atezolizumab works when given to children and adults with SMARCB1 or SMARCA4 deficient tumors that have either come back (relapsed) or do not respond to therapy (refractory). SMARCB1 or SMARCA4 deficiency means that tumor cells are missing the SMARCB1 and SMARCA4 genes, seen with some aggressive cancers that are typically hard to treat. Immunotherapy with monoclonal antibodies, such as tiragolumab and atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
San Francisco, California and other locations
Our lead scientists for Chordoma research studies include Alyssa Reddy.
Last updated: